HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Published online before print June 3, 2003

This Article Full Text (Reprint (PDF)) All Versions of this Article: jlb.0802416v1 74/3/311    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Greil, R. Articles by Johrer, K. Search for Related Content PubMed PubMed Citation Articles by Greil, R. Articles by Johrer, K.

© 2003 by The Society for Leukocyte Biology
Journal of Leukocyte Biology, doi:10.1189/jlb.0802416

Received for publication August 27, 2002.

Accepted for publication March 25, 2003.

Article

Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools

Richard Greil ^*@, Inge Tinhofer ^*, Gabriele Anether ^*, and Karin Johrer

*Department of Internal Medicine, Division of Hematology and Oncology, Laboratory of Molecular Cytology, University of Innsbruck Medical School, Austria; and Tyrolean Cancer Research Institute, Innsbruck, Austria

^@ To whom correspondence should be addressed. E-mail: richard.greil{at}uibk.ac.at.

	Abstract

In the past decade, it was concluded from a number of investigations that death domain-containing members of the tumor necrosis factor-receptor (TNF-R) family and their ligands such as Fas/FasL and TNF-related apoptosis-inducing ligand (TRAIL)-R/TRAIL are essential for maintaining an intact immune system for surveillance against infection and cancer development and that nondeath domain-containing members such as CD30 or CD40 are involved in the fine tuning of this system during the selection process of the lymphatic system. In line with this conclusion are the observations that alterations in structure, function, and regulation of these molecules contribute to autoimmunity and cancer development of the lymphoid system. Besides controlling size and function of the lymphoid cell pool, Fas/FasL and TRAIL-R/TRAIL regulate myelopoiesis and the dendritic cell functions, and severe alterations of these lineages during the outgrowth and expansion of the lymphoid tumors have been reported. It is the aim of this review to summarize what is currently known about the complex role of these two death receptor/ligand systems in normal, disturbed, and neoplastic hemato-/lymphopoiesis and to point out how such knowledge can be used in developing novel, therapeutic options and the problems that will have to be faced along the way.

Key Words: lymphoma • tumor counterattack • novel therapeutic strategies

This article has been cited by other articles:

				S. Maddika, E. P. Booy, D. Johar, S. B. Gibson, S. Ghavami, and M. Los Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway J. Cell Sci., October 1, 2005; 118(19): 4485 - 4493. [Abstract] [Full Text] [PDF]

				T. Zhang, B. A. Lemoi, and C. L. Sentman Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy Blood, September 1, 2005; 106(5): 1544 - 1551. [Abstract] [Full Text] [PDF]

				J. M. Pullar, S. J. Thomson, M. J. King, C. I. Turnbull, R. G. Midwinter, and M. B. Hampton The chemopreventive agent phenethyl isothiocyanate sensitizes cells to Fas-mediated apoptosis Carcinogenesis, May 1, 2004; 25(5): 765 - 772. [Abstract] [Full Text] [PDF]